Objective To study how polyclonal antibodies against ciliary neurotrophic factor (CNTF) reduce botulinum toxin-in- duced axonal sprouting and affect paralytic muscle.Design Experimental study.Participants 20 New Zealand rabbits.Methods In 10 rabbits randomly selected,left superior rectus were as control (Group 1),right superior rectus were injected with botulinum toxin A (BTXA) 2.5U (Group 3).At 14th day,bilateral superior recti were taken out under general anaesthesia.In the other 10 rabbits,left su- perior recti were injected equivalent physical saline (NS) as control (Group 2);right superior recti were injected with BTXA 2.5U,after 4 days,injected with 50?l polyclonal antibodies against CNTF at same site (Group 4).And at 14th day,bilateral superior recti were taken out for electron microscopy,dyed with acetylcholinesterase,argentums (Ag) to show nerve axonal sprout,and accounted and mea- sured with Leica microsystems.Main Outcome Measures The mean number of sprouts and the mean total length of sprouts,and the uhrastructure change of muscle by electron microscopy.Results In Group 1,the mean number of sprouts and the mean total length of sprouts were 5.75% and 10.53?m respectively;Group 2 were 6.11% and 11.16?m;Group 3 were 84.04% and 170.71?m;and Group 4 were 54.77% and 68.12?m.The differences were statistically significant (all P=0.000).Electron microscopy showed that after admin- istration BTXA alone (Group 3),muscle atrophied obviously,nerve myelin sheath increased,while the structure of nerve and muscle re- main invariable.The Group 4 showed that local myofilament disrupted and dissolved,degenerative myocytes necrotized and disintegrat- ed into fragments,which led to partial unreversible destroy.Conclusion Polyclonal anti-CNTF can reduce BTXA-induced axonal sprout- ing,lead to partial unreversible destroy of muscle,which may prolong the time of paralytic muscle resuming.It suggests that polyclonal anti-CNTF could prolong the duration of muscle paralyses induced by botulinum toxin.

China ; Conservation of Natural Resources ; Electricity

Central Nervous System Neoplasms ; secondary ; Humans ; Neoplasm Metastasis ; Neuroblastoma ; pathology

Diabetes Mellitus ; Diabetic Neuropathies ; drug therapy ; physiopathology ; Drugs, Chinese Herbal ; pharmacology ; therapeutic use ; Humans ; Inventions

Drugs, Chinese Herbal ; pharmacology ; Humans ; Kidney Failure, Chronic ; mortality ; physiopathology ; Renal Dialysis ; methods ; mortality ; Survival Rate

ObjectiveTo investigate the efficacy and toxicity of docetaxel combined with compound tegafur capsule(S-1)on anthracycline-refractory recurrent metastatic breast cancer (ARMBC).Methods Thirty-eight ARMBC patients were given intravenous 70 mg/m2 docetaxel at day 1,and oral 60 mg/m2 S-1twice every day at day 1 to 14.Every 3 weeks was one cycle and each patient received at least two cycles.ResultsAfter treatment,among these 38 patients,there was 2 complete response (CR) (5.3 ％),20 partial response (PR) (52.6 ％),10 stable disease (SD) (26.3 ％),and 6 progressive disease (PD) (15.8 ％).Overall objective response rate was 57.9 ％ (95 ％ confidence intervaal: 42.6 ％-74.2 ％) while clinical benefit response rate was 73.7 ％ (95％ confidence interval: 58.4 ％-89.1％).The median time to progression (TTP) was 7.8 months(95 ％ confidence interval:6.7-8.9 months),and median overall survival time(OS)was 15.7 months (95 ％ confidence interval: 12.9-18.8 months).The main toxic reaction was myelosuppression,and grade Ⅲ and Ⅳ adverse events including leucopenia occurred in 21.1％ of all cases.Most common grade Ⅰ and Ⅱ adverse events,such as hand-foot syndrome,nausea,vomiting,diarrhea,liver dysfunction,and oral mucositis,were tolerable.ConclusionGood clinical efficacy is achieved in the therapy of metastatic breast cancer with docetaxel and S-1 combination regimen and toxic reaction is tolerable.

Abdominal Neoplasms ; metabolism ; pathology ; Adolescent ; Diagnosis, Differential ; Fibroblasts ; metabolism ; pathology ; Groin ; Histiocytoma, Malignant Fibrous ; metabolism ; pathology ; Humans ; Keratins ; metabolism ; Lymph Nodes ; metabolism ; pathology ; Lymphoma ; metabolism ; pathology ; Male ; Melanoma ; metabolism ; pathology ; Vimentin ; metabolism

Animals ; Cell Differentiation ; drug effects ; Cell Proliferation ; drug effects ; Central Nervous System ; drug effects ; growth & development ; Female ; Organophosphorus Compounds ; toxicity ; Pesticides ; toxicity ; Pregnancy ; Rats

Objective To investigate the effects of liver function and tumor markers by nucleoside analogues Entecavir on patients with liver cirrhosis after hepatitis B.Methods 90 patients with liver cirrhosis after hepatitis B were selected, according to the different drugs were divided into experimental group and control group.Liver function and levels of tumor markers were compared after experiment.Results Two groups of patients with male to female ratio, average age, course of disease, no significant difference in general data of hepatitis B virus DNA content, comparable (P>0.05);Compared with the control group, the experimental group HBV DNA level is low, the negative rate was significantly higher (P<0.05);Compared with the control group, the experimental group ALT, AST and TBiL levels were significantly increased(P<0.05), ChE, AlB were significantly decreased (P<0.05);Compared with the control group, the experimental group CEA, AFP, CA125 and lower CA199 levels (P<0.05).Conclusion Nucleoside drugs can significantly improve liver function in patients with liver cirrhosis after hepatitis Band tumor markers indicators, and it is significance for treatment of liver cirrhosis after hepatitis.

Diclofenac potassium delayed-sustained release pellets were prepared by double-layer coating method with ethylcellulose aqueous dispersion.The effects of release condition and pellet compositions on the in vitro drug release were evaluated.The formulation was optimized by the central composite design-response surface methodology.It was shown that the pH of the media greatly affected the in vitro drug release of the pellets while the viscosity of the media had little influence.Drug release from the pellets was related to the proportion of the inner coat to the outer coat and the amount of pore forming agent in the outer coat.The optimization of the formulation could be achieved by the central composite design-response surface methodology.